Literature DB >> 23753040

A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer.

Susan Spillane1, Kathleen Bennett, Linda Sharp, Thomas I Barron.   

Abstract

BACKGROUND: Preclinical evidence suggests a beneficial effect of metformin in colorectal cancer. This study aimed to investigate associations between metformin exposure and colorectal cancer-specific survival using population-level data.
METHODS: Adult patients with stage I-III colorectal cancer diagnosed from 2001 to 2006 were identified from the National Cancer Registry Ireland. Use of metformin and other antidiabetic medications was determined from a linked national prescription claims database. Multivariate Cox regression was used to estimate hazard ratios (HR) with 95% confidence intervals (CI) for associations between prediagnostic metformin exposure (versus nonmetformin antidiabetic drugs) and colorectal cancer-specific mortality. Models were stratified by antidiabetic drug coprescription and intensity of metformin exposure.
RESULTS: The cohort included 207 diabetics who received metformin, 108 diabetics not exposed to metformin, and 3,501 nondiabetic patients. In multivariate analyses, a nonsignificant reduction in colorectal cancer-specific mortality was observed for metformin-exposed patients relative to other treated diabetics (HR, 0.61; 95% CI, 0.37-1.01). In stratified analyses, no significant association was observed for patients receiving low-intensity metformin or metformin in combination with other antidiabetic drugs. High-intensity exclusive metformin use was associated with a significant reduction in colorectal cancer-specific mortality (HR, 0.44; 95% CI, 0.20-0.95).
CONCLUSIONS: Significant associations between metformin exposure and colorectal cancer-specific mortality were observed only for high-intensity exclusive metformin use in the diabetic cohort. IMPACT: This study provides moderate evidence of an association between metformin exposure and improved colorectal cancer survival in a diabetic population. Additional studies in larger cohorts, with detailed information on diabetes severity, are required to confirm these results. ©2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23753040     DOI: 10.1158/1055-9965.EPI-13-0347

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

Review 1.  Metformin and cancer.

Authors:  Natalia G Vallianou; Angelos Evangelopoulos; Christos Kazazis
Journal:  Rev Diabet Stud       Date:  2014-02-10

2.  Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.

Authors:  Vijayalekshmi Nair; Sandeep Sreevalsan; Riyaz Basha; Maen Abdelrahim; Ala Abudayyeh; Aline Rodrigues Hoffman; Stephen Safe
Journal:  J Biol Chem       Date:  2014-08-20       Impact factor: 5.157

3.  Metformin and breast cancer stage at diagnosis: a population-based study.

Authors:  I C Lega; K Fung; P C Austin; L L Lipscombe
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

Review 4.  Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.

Authors:  Ming Yin; Jie Zhou; Edward J Gorak; Fahd Quddus
Journal:  Oncologist       Date:  2013-11-20

Review 5.  The role of an anti-diabetic drug metformin in the treatment of endocrine tumors.

Authors:  Shilpa Thakur; Brianna Daley; Joanna Klubo-Gwiezdzinska
Journal:  J Mol Endocrinol       Date:  2019-08       Impact factor: 5.098

6.  Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system.

Authors:  Jie Lin; Abegail Gill; Shelia H Zahm; Corey A Carter; Craig D Shriver; Joel A Nations; William F Anderson; Katherine A McGlynn; Kangmin Zhu
Journal:  Int J Cancer       Date:  2017-05-04       Impact factor: 7.396

7.  Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Authors:  Claudio Vernieri; Fabio Galli; Laura Ferrari; Paolo Marchetti; Sara Lonardi; Evaristo Maiello; Rosario V Iaffaioli; Maria G Zampino; Alberto Zaniboni; Sabino De Placido; Maria Banzi; Azzurra Damiani; Daris Ferrari; Gerardo Rosati; Roberto F Labianca; Paolo Bidoli; Giovanni L Frassineti; Mario Nicolini; Lorenzo Pavesi; Maria C Tronconi; Angela Buonadonna; Sabrina Ferrario; Giovanni Lo Re; Vincenzo Adamo; Emiliano Tamburini; Mario Clerico; Paolo Giordani; Francesco Leonardi; Sandro Barni; Andrea Ciarlo; Luigi Cavanna; Stefania Gori; Saverio Cinieri; Marina Faedi; Massimo Aglietta; Maria Antista; Katia F Dotti; Francesca Galli; Maria Di Bartolomeo
Journal:  Oncologist       Date:  2019-01-03

8.  Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer.

Authors:  Jessica K Paulus; Christina D Williams; Furha I Cossor; Michael J Kelley; Robert E Martell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-05       Impact factor: 4.254

9.  A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival.

Authors:  R Ramjeesingh; C Orr; C S Bricks; W M Hopman; N Hammad
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

10.  Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer.

Authors:  Teodoro Vargas; Juan Moreno-Rubio; Jesús Herranz; Paloma Cejas; Susana Molina; Margarita González-Vallinas; Ricardo Ramos; Emilio Burgos; Cristina Aguayo; Ana B Custodio; Guillermo Reglero; Jaime Feliu; Ana Ramírez de Molina
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.